The information on this website is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before starting any peptide therapy or other compounds.
Sponsored by
Joaking Fitness - Entrendor personal
Anti-aging Neuropeptides Mitochondrial Peptides Under research

Humanin

Also known as: HN

Humanin is one of the first mitochondria-derived peptides (MDPs) discovered. It consists of 21 or 24 amino acids depending on whether it is transcribed within the cell or outside it. It exhibits a powerful neuroprotective and cytoprotective effect, initially discovered rescuing neurons from the toxic effects of beta-amyloid plaques present in Alzheimer's disease.

Mechanism of action

  • Binds to specific cell membrane receptors (such as the trimeric CNTFR/WSX-1/gp130 receptor) or acts intracellularly by binding to BAX.
  • By binding to BAX (a pro-apoptotic protein), it prevents it from causing cell damage and halts apoptosis (cell death) induced by cellular stress.
  • Significantly reduces the formation of reactive oxygen species (ROS) and improves survival under ischemic conditions.

Uses & indications

  • Neurological protection: Strong therapeutic potential for Alzheimer's, ALS, and ischemic brain damage.
  • Eye health: Prevention of macular degeneration.
  • Metabolic protection: Improves insulin sensitivity and prevents vascular endothelial damage.

Effects

Drastic rescue of cells under severe toxic stress, preservation of cognitive function in neurodegenerative models, and delay of cellular aging processes.

Considerations & contraindications

  • Its levels naturally decline with age, so experimental supplementation seeks to restore young adult levels.

Regulatory approval

Basic research and animal models.

Dosage

Experimental human doses are not standardized; typically around 1 to 5mg administered via injection.

Storage

Lyophilized at -20°C.
Technical data
Regulatory status Under research
Molecular weight 2687.2 Da
Half-life Corto, pero induce cambios de supervivencia a largo plazo
Administration routes Subcutánea, Intravenosa, Tópica ocular
Reconstitution ← Back to catalog

If you detect incorrect information, tell us what is wrong and provide a scientific source to support it.